Navigation Links
NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
Date:2/29/2008

IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals Inc. (OTC Bulletin Board: NURX) today announced it has retained Russo Partners LLC for the provision of investor relations and corporate communications counsel.

The healthcare communications firm will implement a comprehensive program that consists of investor targeting, the scheduling of presentations at industry conferences, media relations and other corporate visibility initiatives. Russo Partners will collaborate with OTC Communications, a division of Rx Communications Group LLC, on the implementation of some program tactics.

"We are in a unique position with a clinical-stage pipeline and large portfolio of retinoid and rexinoid compounds that were developed over a number of years by world-class researchers who have joined the NuRx scientific team," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to initiate three to four clinical trials this year. Therefore, the need to support the associated news flow prompted us to select Russo Partners to develop and lead our communications efforts with Wall Street and the biotech/pharmaceuticals community. The firm has the healthcare industry expertise, senior-level talent and investor and media relationships that were critical to our selection of a communications partner."

Russo Partners LLC, formerly Noonan Russo, provides strategic communications services to emerging healthcare - biotech, medical device, diagnostics and healthcare services - companies worldwide. Headquartered in New York City, the firm has a West Coast office in San Diego and an affiliated office in London. For more information, visit http://www.russopartnersllc.com.

NuRx Pharmaceuticals Inc. is an emerging biotech company focused on the development of retinoid and rexinoid compounds with application in oncology (treatment, prevention and adjunctive supportive therapy), the treatment of diabetes, the regulation of lipid metabolism and bone metabolism and repair. The company's lead compounds are (1) NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha subtype- specific agonist for the treatment of acute leukemia; and (3) NRX4310, a function selective receptor modulator for the treatment and prevention of chemotherapy-induced neutropenia. Located in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

CONTACTS: Media

David Schull

(212) 845-4271

david.schull@russopartnersllc.com

Investors

Rhonda Chiger

(917) 322-2569

rchiger@rxir.com


'/>"/>
SOURCE NuRx Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
2. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
3. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
10. JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)
11. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage ... fingerprint recognition for secure access, voice recognition for hands-free communication, and facial recognition ... interacting with biometrics technology today. But if they asked Joey Pritikin, Vice ...
(Date:4/27/2016)... Baltimore, MD (PRWEB) , ... April 27, 2016 ... ... appointed Greg Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist ... of plant pathogen detection. , PathSensors deploys the CANARY® test platform for ...
(Date:4/27/2016)... ReportsnReports.com adds 2016 global ... on US, EU, China ... healthcare business intelligence collection of its growing online ... on the Flow Cytometry market spread across 153 ... tables and figures is now available at ...
(Date:4/26/2016)... ... , ... Mr. Palmer created the RPO business for Ceridian and lead the ... services contract in the U.S. intelligence community with The SI (a Lockheed Martin divestiture). ... founder of Accolo. “We are growing and his experience guiding our expansion is ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):